⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 38 in last 7 days 🍎 Food: 116 in last 7 days 🧸 Products: 98 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 38 in last 7 days 🍎 Food: 116 in last 7 days 🧸 Products: 98 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT June 8, 2026

Glimepirid 1A Pharma 4 mg - Tabletten (Tablette)

📷 Wikipedia: Glimepiride · Source
Glimepirid 1A Pharma 4 mg - Tabletten (Tablette)
📷 Wikipedia: Glimepiride · Source
Glimepirid 1A Pharma 4 mg tablets are subject to a parallel export ban due to manufacturing capacity shortages. The affected packs are the 30-tablet box with blister packaging, which has been unavailable since June 8, 2026.
⚠️
Shortage ongoing
GLIMEPIRID is currently in short supply in AT.
📈 Timeline
2 days active so far
June 9, 2026 June 10, 2026

What is this? Glimepirid is a medicine for diabetes. It helps control blood sugar.

What's happening? The tablets are not available right now. There is a shortage.

Does this affect me? If you take this medicine, you may be affected.

What should I do? Ask your pharmacist or doctor for advice. Do not stop taking your medicine without talking to them first.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
GLIMEPIRID
Agency-published detail

🚫 Parallel export ban active · ATC: A10BB12 · Reason: Kapazitätsengpässe bei der Herstellung · Marketing authorisation holder: 1 A Pharma GmbH, Jakov-Lind-Straße 5/3.05, 1020 Wien, Österreich · Affected packs: 30 Stück Schachtel, Blisterpackung [Nicht verfügbar, since 2026-06-08]

First published
June 8, 2026
Last refreshed by us
1 hour ago
Severity (as classified)
Low
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

Low AT resolved 2 weeks ago

Glimepirid 1A Pharma 3 mg - Tabletten (Tablette)

Glimepiride 1A Pharma 3 mg tablets are subject to a parallel export ban.
Medium AT 1 month ago

Glimepirid Hexal 2 mg - Tabletten (Tablette)

Glimepirid Hexal 2 mg tablets are subject to a parallel export ban.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Glimepirid 1A Pharma 4 mg - Tabletten (Tablette). Glimepirid 1A Pharma 4 mg tablets are subject to a parallel export ban due to manufacturing capacity shortages. The affected packs are the 30-tablet box with blister packaging, which has been unavailable since June 8, 2026.
▸ When was this alert issued?
This alert was issued on June 8, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Low risk. A low risk means harm is unlikely under normal use. The alert is informational but still worth reading.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.